Lysosomal storage diseases (LSDs) are inborn errors caused by genetic defects of lysosomal enzymes associated with the excessive accumulation of natural substrates and neurovisceral manifestations. Until now, enzyme replacement therapy (ERT) with human lysosomal enzymes produced by genetically engineered mammalian cell lines has been applied clinically to treat several LSDs. ERT is based on the incorporation of N-glycosylated lysosomal enzymes through binding to glycan receptors on the surface of target cells and delivery to lysosomes. However, ERT has several disadvantages, including di‹culty in mass producing human enzymes, dangers of pathogen contamination, and high cost. Recently, we have succeeded in producing transgenic silkworms which overexpress human lysosomal enzymes in silk glands, and have puriˆed active and functional enzymes from middle silk glands and cocoons. Silk gland-and cocoonderived human enzymes carrying high-mannose and pauci-mannose N-glycans are endocytosed by monocytes via the mannose receptor pathway; these were then delivered to lysosomes. Human cathepsin A (Ctsa) precursor proteins puried from the cocoons have been found to suppress microglial activation in the brains of Ctsa-deˆcient mice; this deˆciency is caused by a splicing defect, and serves as a galactosialidosis model associated with the combination of a deˆciency of lysosomal neuraminidase 1 (NEU1) and the accumulation of sialyloligosaccharides. Transgenic silkworms overexpressing human lysosomal enzymes in silk glands could serve as a future bioresource to provide safe therapeutic enzymes for the treatment of LSDs. The combination of recent developments in transglycosylation technology with microbial endoglycosidases will aid in the development of therapeutic glycoproteins as bio-medicines.
. Lysosomal Diseases and Enzyme Replacement Therapy (ERT) by Using Recombinant Human Lysosomal Enzymes
ERT has been clinically applied to several lysosomal diseases involving visceral symptoms, including Gaucehr disease, Fabry disease, Pompe disease, Wolman disease and mucopolysaccharidoses (I, II, IV, VI and VII). The ERT is based on endocytic transport to lysosomes of lysosomal enzymes produced by mammalian cell lines with N-glycans carrying terminal mannose (Man) or mannose-6-phosphate (M6P) residues through binding with cell surface glycan receptors, including mannose receptor (MR) and cation-independent mannose-6-phosphate receptor (CI-M6PR), which recognize the terminal Man and M6P residues, respectively. Usually, therapeutic enzymes are intravenously injected to the patients at a dose of 1 mg to 20 mg of enzyme per kg body weight, every two weeks. And, continuous administration is necessary to maintain the clinical eŠectiveness. 
